INT15613

Context Info Confidence 0.59 First Reported 1991 Last Reported 2010 Negated 0 Speculated 5 Reported most in Abstract Documents 160 Total Number 165 Disease Relevance 71.08 Pain Relevance 65.08

lipid binding (Ptgs2) nuclear envelope (Ptgs2) oxidoreductase activity (Ptgs2) endoplasmic reticulum (Ptgs2) nucleus (Ptgs2) enzyme binding (Ptgs2)

Anatomy Link Frequency colon 9 spinal 5 tail 2 brain 2 temporomandibular joint 2 Ptgs2 (Rattus norvegicus)

Pain Link Frequency Relevance Heat Inflammation 280 100.00 COX2 132 100.00 aspirin 48 100.00 cOX1 43 100.00 acular 17 100.00 metalloproteinase 11 100.00 Analgesic 128 99.96 cINOD 187 99.92 cytokine 40 99.90 Neuropathic pain 14 99.84

Disease Link Frequency Relevance Heat INFLAMMATION 407 99.98 Hemorrhage 6 99.92 Peptic Ulcer 40 99.84 Neuropathic Pain 36 99.84 Cardiovascular Disease 11 99.84 Fracture Healing 5 99.84 Colon Cancer 23 99.74 Pain 354 99.60 Cancer 135 99.60 Hyperalgesia 77 99.60

Sentences Mentioned In

Key:

Protein

Mutation

Event

Anatomy

Negation

Speculation

Pain term

Disease term

Selective cyclooxygenase-2 inhibition reduces carrageenan oedema and associated spinal c-Fos expression in the rat.

Negative_regulation (inhibition) of cyclooxygenase-2 in spinal associated with pressure and volume under development

1) Confidence 0.59 Published 1996 Journal Brain Res. Section Title Doc Link 8739641 Disease Relevance 0.10 Pain Relevance 0.12

Pre-administered NS-398 (0.1, 1 and 10 mg/kg p.o.), a selective cyclooxygenase-2 inhibitor without gastro-intestinal side-effects, dose-dependently reduced carrageenan evoked spinal c-Fos expression (16 +/- 4%, 32 +/- 3% and 56 +/- 5% reduction, respectively) at 3 h after intraplantar carrageenan.

Negative_regulation (inhibitor) of cyclooxygenase-2 in spinal

2) Confidence 0.59 Published 1996 Journal Brain Res. Section Abstract Doc Link 8739641 Disease Relevance 0.07 Pain Relevance 0.11

L-745,337: a selective inhibitor of cyclooxygenase-2 elicits antinociception but not gastric ulceration in rats.

Negative_regulation (inhibitor) of cyclooxygenase-2 associated with antinociception and analgesic

3) Confidence 0.59 Published 1994 Journal Neuropharmacology Section Title Doc Link 7760984 Disease Relevance 0.09 Pain Relevance 0.56

3,4-Diaryl-5-hydroxyfuranones: highly selective inhibitors of cyclooxygenase-2 with aqueous solubility.

Negative_regulation (inhibitors) of cyclooxygenase-2 associated with cox2

4) Confidence 0.59 Published 2003 Journal Bioorg. Med. Chem. Lett. Section Title Doc Link 12643942 Disease Relevance 0 Pain Relevance 0.42

Meloxicam, a non-steroidal anti-inflammatory drug, is a preferential inhibitor of cyclooxygenase-2 and has demonstrated potent analgesic and anti-inflammatory activity after oral administration.

Negative_regulation (inhibitor) of cyclooxygenase-2 associated with inflammation and analgesic

5) Confidence 0.59 Published 2002 Journal Skin Pharmacol. Appl. Skin Physiol. Section Abstract Doc Link 11867967 Disease Relevance 0.42 Pain Relevance 0.57

Derivatives of 2,6-di-tert-butylphenol, whose members may act as PGHS-1/PGHS-2 inhibitors, selective PGHS-2 inhibitors or PGHS/5-LO dual inhibitors, are novel anti-inflammatory compounds that are devoid of GI irritating effects and do not affect the rate of pre-existing gastric ulcer healing.

Negative_regulation (inhibitors) of PGHS-2 associated with inflammation and peptic ulcer

6) Confidence 0.58 Published 1998 Journal J. Pharmacol. Exp. Ther. Section Abstract Doc Link 9765350 Disease Relevance 1.11 Pain Relevance 0.32

Suppression of azoxymethane-induced aberrant crypt foci in rat colon by nimesulide, a selective inhibitor of cyclooxygenase 2.

Negative_regulation (inhibitor) of cyclooxygenase 2 in colon associated with aberrant crypt foci and cox2

7) Confidence 0.58 Published 1996 Journal J. Cancer Res. Clin. Oncol. Section Title Doc Link 8601574 Disease Relevance 0.84 Pain Relevance 0.29

Comparison of indomethacin and nimesulide, a selective cyclooxygenase-2 inhibitor, on key pathophysiologic steps in the pathogenesis of nonsteroidal anti-inflammatory drug enteropathy in the rat.

Negative_regulation (inhibitor) of cyclooxygenase-2 associated with inflammation, enteropathy and cinod

8) Confidence 0.57 Published 1998 Journal Scand. J. Gastroenterol. Section Title Doc Link 9712237 Disease Relevance 0.19 Pain Relevance 0.10

A recently described selective inhibitor of PGHS-2, NS-398, was approximately 30 times more potent in inhibiting PGHS-2 than PGHS-1, and diclofenac was approximately 10 times more potent.

Negative_regulation (inhibiting) of PGHS-2 associated with diclofenac

9) Confidence 0.57 Published 1997 Journal J. Bone Miner. Res. Section Abstract Doc Link 9258749 Disease Relevance 0.33 Pain Relevance 0.62

We cultured skeletal muscle satellite cells from 9-month-old Sprague-Dawley rats and exposed them to naproxen sodium (a nonselective cyclooxygenase inhibitor), NS-398 (a selective cyclooxygenase-2 inhibitor), and SC-560 (a selective cyclooxygenase-1 inhibitor) for 96 h.

Negative_regulation (inhibitor) of cyclooxygenase-2 in skeletal muscle satellite cells

10) Confidence 0.57 Published 2004 Journal Muscle Nerve Section Abstract Doc Link 15372441 Disease Relevance 0.21 Pain Relevance 0.12

Cyclooxygenase-2 inhibition alone resulted in decreased satellite cell proliferation, and inhibition of both cyclooxygenase-1 and cyclooxygenase-2 resulted in decreased satellite cell differentiation and fusion.

Negative_regulation (inhibition) of cyclooxygenase-2 in satellite cell

11) Confidence 0.57 Published 2004 Journal Muscle Nerve Section Abstract Doc Link 15372441 Disease Relevance 0.24 Pain Relevance 0.12

The use of a selective cyclooxygenase-2 inhibitor over nonspecific cyclooxygenase inhibitors in the treatment of muscle injuries is not supported.

Negative_regulation (inhibitor) of cyclooxygenase-2 in muscle associated with injury

12) Confidence 0.57 Published 2004 Journal Muscle Nerve Section Abstract Doc Link 15372441 Disease Relevance 0.36 Pain Relevance 0.12

Within the limits of the present study, it can be concluded that selective cyclooxygenase-2 inhibitors may reduce bone healing in calvarial defects in rats after continuous administration.

Negative_regulation (inhibitors) of cyclooxygenase-2

13) Confidence 0.57 Published 2005 Journal Brazilian oral research Section Abstract Doc Link 16491262 Disease Relevance 0.05 Pain Relevance 0.13

A rat model was used to investigate the efficacy of nimesulide, a selective cyclooxygenase-2 inhibitor, in the prevention of adhesion formation.

Negative_regulation (inhibitor) of cyclooxygenase-2 associated with adhesions

14) Confidence 0.55 Published 2001 Journal Hum. Reprod. Section Abstract Doc Link 11473974 Disease Relevance 0.55 Pain Relevance 0.13

The effects of misoprostol and two drugs that show in vitro selectivity for inhibiting cyclooxygenase 2 (nabumetone and L745,337) were also assessed.

Negative_regulation (inhibiting) of cyclooxygenase 2

15) Confidence 0.54 Published 1995 Journal Gastroenterology Section Body Doc Link 7615202 Disease Relevance 0.09 Pain Relevance 0

The potency of ibuprofen as an inhibitor of anandamide metabolism was of the same order of magnitude as required for inhibition of cyclooxygenase-2 in cell-free systems and of the peak plasma concentrations of this drug following a 2 x 200 mg dose regimen.

Negative_regulation (inhibition) of cyclooxygenase-2 in plasma associated with potency

16) Confidence 0.54 Published 1997 Journal Pharmacol. Toxicol. Section Abstract Doc Link 9060042 Disease Relevance 0 Pain Relevance 0.26

A series of 3,4-diaryloxazolones were prepared and evaluated for their ability to inhibit cyclooxygenase-2 (COX-2).

Negative_regulation (inhibit) of cyclooxygenase-2

17) Confidence 0.50 Published 2000 Journal J. Med. Chem. Section Abstract Doc Link 10649977 Disease Relevance 0.18 Pain Relevance 0.12

The present results suggest that, in addition to cyclooxygenase-2 inhibition, the antinociceptive effect of rofecoxib could also involve activation of the L-arginine-NO-cyclic GMP (cGMP) pathway, followed by opening of ATP-sensitive K+ channels at the peripheral level.

Negative_regulation (inhibition) of cyclooxygenase-2 associated with antinociceptive

18) Confidence 0.50 Published 2004 Journal Eur. J. Pharmacol. Section Abstract Doc Link 14744603 Disease Relevance 0.14 Pain Relevance 0.36

The antinociceptive effect of rofecoxib, a preferential inhibitor of cyclooxygenase-2, was assessed in the pain-induced functional impairment model in the rat.

Negative_regulation (inhibitor) of cyclooxygenase-2 associated with pain and antinociceptive

19) Confidence 0.50 Published 2004 Journal Eur. J. Pharmacol. Section Abstract Doc Link 14744603 Disease Relevance 0.18 Pain Relevance 0.29

In addition, it has been demonstrated that inhibition of cyclooxygenase-2 is responsible for the therapeutic effects of nonsteroidal anti-inflammatory drugs (NSAIDs).

Negative_regulation (inhibition) of cyclooxygenase-2 associated with inflammation and cinod

20) Confidence 0.47 Published 2003 Journal Eur. J. Pharmacol. Section Abstract Doc Link 12559369 Disease Relevance 0.32 Pain Relevance 0.92

General Comments

This test has worked.